Daclatasvir plus asunaprevir provided sustained virological response in @ ( @ % , @ % CI @-@ ) patients in the treatment-naive cohort , @ ( @ % , @-@ ) in the non-responder cohort , and @ ( @ % , @-@ ) in the ineligible , intolerant , or ineligible and intolerant cohort .